secwatch.observer — SEC 8-K summary
======================================

Issuer:     Editas Medicine, Inc. (EDIT)
CIK:        0001650664
Form:       8-K
Filed at:   2023-11-22T23:59:59+00:00
Accession:  0001650664-23-000026
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Editas Medicine amends severance plan, extending CEO benefits to 18 months post-change-of-control
--------------------------------------------------------------------------------

- Amended plan extends change-in-control termination window to include 3 months prior to a change in control.
- Non-change-in-control termination now includes term for Good Reason; requires termination >3 months prior to change.
- CEO severance: base salary continuation extended to 18 months (was 12) and COBRA contributions also to 18 months.
- Plan covers named executive officers and other designated employees under an unfunded welfare benefit plan.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1650664/000165066423000026/0001650664-23-000026-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1650664/000165066423000026/edit-20231116.htm
  HTML page:      https://secwatch.observer/filing/0001650664-23-000026

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer